When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
AHA 2022 – Amgen looks good in metabolic disease
With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.
Abbvie grabs an antibody against an elusive target
Bristol Myers Squibb has been trying for years to hit LPA1 with small molecules, but an acquisition by Abbvie signals a new approach.
Bispecifics move beyond cancer
Hitting two targets with one molecule is all the rage in oncology, but Roche and others have taken this work into other disease areas.
Medtech bleeds corporate venture cash
Overall venture investment in the sector remains steady, but the big strategics back off.
No big bang for biopharma buyouts
Pfizer's Covid cash keeps the M&A scene alive, but few other developers dug deep in a quiet third quarter.
